Clinical trials: Malignant Melanoma
Melanoma
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available.
- Trial name
- NCT00431275
- Testing
- CP-675,206
- Where
- 8 sites in United States
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
Melanoma
Sun Exposure and Melanoma in Agricultural Workers
This K07 Career Development Award application is designed to expand Dr. Dennis career development from cancer etiology to cancer prevention and control.
- Trial name
- NCT00901966
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Uveal Melanoma
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
- Trial name
- NCT03417739
- Testing
- BVD-523
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Cutaneous Melanoma, Merkel Cell Carcinoma
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
This phase II trial tests how well EMLA topical cream works in treating pain in patients with skin cancers receiving Technetium 99 injections for a lymphoscintigraphy mapping procedure.
- Conditions
- Cutaneous Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma
- Trial name
- NCT06223659
- Testing
- Eutectic Mixture of Local Anesthetics, Questionnaire Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Melanoma
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning…
- Trial name
- LN-144 (NCT02360579)
- Testing
- Lifileucel
- Where
- 57 sites in United States, France and 6 more
- Volunteers
- 220 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
This is an open label, 2-arm, 1-stage, randomized controlled phase II study in patients with AJCC stage IIIB/C \& -IV melanoma. At baseline tumor assessment (using total body FDG-PET/CT), patients should be free from measurable…
- Trial name
- DC-MEL (NCT01676779)
- Testing
- Dendritic cell therapy
- Where
- Belgium
- Volunteers
- 88 people
- Sponsor
- Universitair Ziekenhuis Brussel
Non-melanoma Skin Cancer, Carcinoma, Squamous Cell
Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
A common long-term side effect of anti-rejection (immunosuppressant) medications is skin cancer. This pilot clinical trial evaluates the feasibility of conducting a larger pivotal trial to examine the efficacy and safety of…
- Conditions
- Non-melanoma Skin Cancer, Carcinoma, Squamous Cell, Carcinoma, Basal Cell
- Trial name
- SPRINTR-Pilot (NCT03769285)
- Testing
- Nicotinamide
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Women's College Hospital
Advanced Solid Tumor, Melanoma
VSV-02 Compassionate Use in Advanced Solid Tumors
This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational drug called VSV-02 Injection, which is developed by…
- Conditions
- Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer
- Trial name
- NCT07260591
- Testing
- VSV-02 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Melanoma Stage III, Melanoma Stage IV
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
The primary objective of this Phase 1 clinical trial is to evaluate the feasibility and tolerability of a novel generation of gene-modified tumor infiltrating lymphocytes (TILs) in a cohort of 10 patients aged 18-75 diagnosed…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Melanoma
- Trial name
- ADP-TILIL7 (NCT06204991)
- Testing
- ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- Inge Marie Svane
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells.
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer
- Trial name
- NCT07555210
- Testing
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jessica Mezzanotte Sharpe
Esophageal and/or Cardia Cancer, Melanoma
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal…
- Conditions
- Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)
- Trial name
- NCT07518043
- Testing
- HLX18, OPDIVO®
- Where
- 7 sites in China
- Volunteers
- 174 people
- Sponsor
- Shanghai Henlius Biotech
Ocular Sebaceous Carcinoma, Ocular Basal Cell Carcinoma
Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers
The study involves enrollment of patients with sebaceous carcinoma, Merkel's carcinoma, Porocarcinoma, Melanoma, and squamous cell Ca of the ocular surface and adnexa both primary and relapsed after surgical and/or…
- Conditions
- Ocular Sebaceous Carcinoma, Ocular Basal Cell Carcinoma, Ocular Surface Squamous Neoplasia, Merkel Cell Carcinoma, Unspecified
- Trial name
- BLS (NCT05797415)
- Testing
- Sentinel Lymph Node Biopsy
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Melanoma (Skin)
Fotemustine in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as fotemustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- MGFOT1 (NCT00560118)
- Testing
- fotemustine
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Refractory Cutaneous Melanoma
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory…
- Trial name
- NCT05200143
- Testing
- Ipilimumab, Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Providence Health & Services
Melanoma
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
The main purpose of this study is to evaluate the safety of Vemurafenib in combination with Metformin in melanoma patients. The phase II part of the study will also evaluate the clinical activity of the combined regiment.
- Trial name
- NCT01638676
- Testing
- Vemurafenib, Metformin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Louisville
Non-melanoma Skin Cancer, Basal Cell Carcinoma
T-VEC in Non-melanoma Skin Cancer
Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer.
- Conditions
- Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma, Cutaneous Lymphoma
- Trial name
- 20139157 T-VEC (NCT03458117)
- Testing
- Talimogene Laherparepvec (T-VEC)
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- University of Zurich
RAS Mutation, Ras (Kras or Nras) Gene Mutation
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the…
- Conditions
- RAS Mutation, Ras (Kras or Nras) Gene Mutation, Colorectal Cancer Recurrent, Pancreas Cancer
- Trial name
- NТО-RAS (NCT06229340)
- Testing
- Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab
- Where
- Russia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Malignant Melanoma
CP-675,206 In Patients With Advanced Melanoma
The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma
- Trial name
- NCT00086489
- Testing
- CP-675,206
- Where
- 9 sites in United States
- Volunteers
- 118 people
- Sponsor
- AstraZeneca